StockData
Petros Pharmaceuticals, Inc. logo

Petros Pharmaceuticals, Inc. (PTPI) stock

PTPIOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 5/30
$0.00+0.00 (+5.56%)

Close on Oct 19, 2026Market cap $135.07KP/E –Yield –

Petros Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Petros Pharmaceuticals's R&D Expenses for the twelve months ending Dec 31, 2024 was $2.62M, up 8.5% year over year. For fiscal 2024 it was $2.62M, up 8.5% from the year before. The highest annual figure on record is $2.62M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2024Dec 31, 2024$2.62M+8.5%
FY2023Dec 31, 2023$2.41M+38.4%
FY2022Dec 31, 2022$1.74M-2.7%
FY2021Dec 31, 2021$1.79M+289.1%
FY2020Dec 31, 2020$459.64K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2024Dec 31, 2024$101.95K-87.8%
Q3 FY2024Sep 30, 2024$588.36K+51.2%
Q2 FY2024Jun 30, 2024$368.80K-57.4%
Q1 FY2024Mar 31, 2024$1.56M+387.6%
Q4 FY2023Dec 31, 2023$834.33K+369.4%
Q3 FY2023Sep 30, 2023$389.09K-47.1%
Q2 FY2023Jun 30, 2023$866.58K+105.7%
Q1 FY2023Mar 31, 2023$319.09K-21.3%
Q4 FY2022Dec 31, 2022$177.76K-64.5%
Q3 FY2022Sep 30, 2022$735.92K+3736.7%
Q2 FY2022Jun 30, 2022$421.24K+177.4%
Q1 FY2022Mar 31, 2022$405.36K+1000.7%
Q2 FY2021Jun 30, 2021$500.05K+280.0%
Q1 FY2021Mar 31, 2021$19.18K-86.2%
Q4 FY2020Dec 31, 2020$151.84K–
Q3 FY2020Sep 30, 2020$36.83K–
Q2 FY2020Jun 30, 2020$131.58K–
Q1 FY2020Mar 31, 2020$139.39K–

More Petros Pharmaceuticals figures

See a number that looks wrong?